The Priority Review

The stream · Daily digest

The stream: Saturday, November 7, 2026

2 briefs, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 2

  1. Johnson & Johnson releases new Phase 2 nipocalimab data in Sjögren's disease

    Johnson & Johnson said the Phase 2 DAHLIAS study found that mouth dryness was the most important symptom to improve, with 96% of patients citing it. The study also reported that at least 50% improvement in objective salivary flow was observed in more than twice as many patients receiving 15 mg/kg nipocalimab compared with placebo (33% versus 16%) at Week 24.

    Source: Company press release (PR Newswire), November 7, 2026

  2. Johnson & Johnson reports ICOTYDE achieves 58% ACR20 response in biologic-naïve psoriatic arthritis

    The Phase 3 ICONIC-PsA 1 study met its primary endpoint, with 58% of ICOTYDE-treated patients achieving an ACR20 response versus 41% of placebo at Week 16. Safety data through Week 24 showed no new safety signals and were consistent with the established safety profile of ICOTYDE.

    Source: Company press release (PR Newswire), November 7, 2026